Abiopharma

🔍 FMR LLC (Executive)

Company: Structure Therapeutics Inc. (GPCR)

Report Date: 2025-12-08

Detailed Transactions and Holdings:

• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2025-12-08 | Code: H | nature_of_ownership: F-Prime Capital Partners Life Sciences Advisors Fund VI LP | shares_owned_after: 36,909.00
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2025-12-08 | Code: H | nature_of_ownership: F-Prime Capital Partners Life Sciences Fund VI LP | shares_owned_after: 434,298.00
• Sold 2,127 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 3,393.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1, F1
• Sold 549 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 3,210.00 | transaction_form_type: 4 | Footnotes: F1, F3, F1, F1
• Sold 1,425 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 2,735.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1, F1
• Sold 4,242 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 1,321.00 | transaction_form_type: 4 | Footnotes: F1, F5, F1, F1
• Sold 3,960 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 1.00 | transaction_form_type: 4 | Footnotes: F1, F6, F1, F1
• Sold 25,011 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 39,918.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1, F1
• Sold 6,477 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 37,759.00 | transaction_form_type: 4 | Footnotes: F1, F3, F1, F1
• Sold 16,767 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 32,170.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1, F1
• Sold 49,905 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | shares_owned_after: 15,535.00 | transaction_form_type: 4 | Footnotes: F1, F5, F1, F1
• Sold 46,605 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F6, F1, F1
• Holds 4,546,674 shares of American Depositary Shares (Derivative)
  Date: 2025-12-08 | Code: H | shares_owned_after: 1,515,558.00 | Footnotes: F1, F1, F1

Footnotes:

• F1: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.
• F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $92.29 to $92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
• F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $93.27 to $94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
• F4: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $94.28 to $94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
• F5: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $60.32 to $61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
• F6: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $61.32 to $61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
• REMARKS: Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.